Literature DB >> 12957399

Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig.

Alison A McCormick1, Stephen J Reinl, Terri I Cameron, Fakhrieh Vojdani, Michele Fronefield, Ronald Levy, Daniel Tusé.   

Abstract

We have developed a method for rapidly producing in plants the idiotype regions of the tumor-specific Ig as single-chain Fv (scFv) proteins for use in the treatment of non-Hodgkin's lymphoma. Variable region gene sequences were generated from either a tumor hybridoma or human tumor biopsy cells, and idiotype domains were joined by a novel linker and cloned into a modified tobacco mosaic virus (TMV) vector designed to secrete the scFv protein in infected Nicotiana benthamiana plants. Thirty-eight out of 44 human scFv proteins showed Coomassie visible material in crude secretory (interstitial fluid, IF) extracts, 21 of those between 100 and 800 microg/ml. Eight of these proteins were tested for appropriate idiotype responses in vaccinated mice. In all eight cases, anti-idiotype immune responses were induced with minimal cross reactivity to irrelevant Ig or scFv proteins. Four out of four anti-scFv sera were also shown to recognize the Ig on human tumor cells by flow cytometry analysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957399     DOI: 10.1016/s0022-1759(03)00208-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  16 in total

1.  Second-generation HIV microbicides: continued development of griffithsin.

Authors:  Larry Zeitlin; Michael Pauly; Kevin J Whaley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

2.  Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.

Authors:  A N Meleshko; N A Petrovskaya; N Savelyeva; K P Vashkevich; S N Doronina; N V Sachivko
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

3.  PVX-Cre-mediated marker gene elimination from transgenic plants.

Authors:  L Kopertekh; G Jüttner; J Schiemann
Journal:  Plant Mol Biol       Date:  2004-07       Impact factor: 4.076

4.  Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.

Authors:  A A McCormick; S Reddy; S J Reinl; T I Cameron; D K Czerwinkski; F Vojdani; K M Hanley; S J Garger; E L White; J Novak; J Barrett; R B Holtz; D Tusé; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-21       Impact factor: 11.205

5.  Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems.

Authors:  Patrizia Galeffi; Alessio Lombardi; Immacolata Pietraforte; Flavia Novelli; Monica Di Donato; Maria Sperandei; Andrea Tornambé; Rocco Fraioli; Aline Martayan; Pier Giorgio Natali; Maria Benevolo; Marcella Mottolese; Francisco Ylera; Cristina Cantale; Patrizio Giacomini
Journal:  J Transl Med       Date:  2006-09-29       Impact factor: 5.531

6.  Expression of recombinant antibodies.

Authors:  André Frenzel; Michael Hust; Thomas Schirrmann
Journal:  Front Immunol       Date:  2013-07-29       Impact factor: 7.561

Review 7.  Bulk production of the antiviral lectin griffithsin.

Authors:  Joshua L Fuqua; Krystal Hamorsky; Guruatma Khalsa; Nobuyuki Matoba; Kenneth E Palmer
Journal:  Plant Biotechnol J       Date:  2015-07-14       Impact factor: 9.803

Review 8.  Viral vectors for production of recombinant proteins in plants.

Authors:  Chiara Lico; Qiang Chen; Luca Santi
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

Review 9.  Progress and challenges in the vaccine-based treatment of head and neck cancers.

Authors:  Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-27

Review 10.  Comparative evaluation of recombinant protein production in different biofactories: the green perspective.

Authors:  Matilde Merlin; Elisa Gecchele; Stefano Capaldi; Mario Pezzotti; Linda Avesani
Journal:  Biomed Res Int       Date:  2014-03-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.